Overall, based on the above results and previously published findings we hypothesise that the level of miR-29a is reduced in SSc dermal fibroblasts compared to healthy controls due to upregulation of negative regulator of miR-29a including TGF-β and IL-6 trans-signaling [15]. The gene discussed is IL6; the disease is systemic sclerosis.